[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100301098":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":68,"centralContacts":72,"locations":82,"responsibleParty":102,"collaborators":38,"id":105,"slug":106,"hasResults":107,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":107,"sex":113,"minAge":114,"maxAge":38,"enrollmentInfo":115,"targetDuration":38,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":38,"overallStatus":84,"whyStopped":38,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Ohio State University Comprehensive Cancer Center","OTHER",[8,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm I (UC)","ACTIVE_COMPARATOR","Patients receive usual care and undergo collection of tumor tissue and blood sample for the repository. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC\u002FDS.",[13,14,15,16,17,18,19],"Other: Best Practice","Procedure: Biospecimen Collection","Other: Laboratory Biomarker Analysis","Other: Medical Chart Review","Other: Quality-of-Life Assessment","Other: Questionnaire Administration","Behavioral: Smoking Cessation Intervention",{"label":21,"type":22,"description":23,"interventionNames":24},"Arm II (AGIT\u002FDS)","EXPERIMENTAL","Patients undergo collection of tumor tissue for analysis using FoundationOne assay and blood sample for analysis using FoundationACT blood circulating tumor DNA assay. Patients who smoke or have recently quit smoking and their household members who smoke may also undergo smoking cessation via usual care or NCCN driven-CTC\u002FDS.",[14,15,16,17,18,19],[26,33,39,42,46,52,58,61],{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Best Practice","Receive usual care",[9],[31,32],"standard of care","standard therapy",{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":38},"PROCEDURE","Biospecimen Collection","Undergo collection of tumor tissue and blood sample for repository",[9],null,{"type":34,"name":35,"description":40,"armGroupLabels":41,"otherNames":38},"Undergo tumor tissue and blood sample for AGIT\u002FDS",[21],{"type":6,"name":43,"description":44,"armGroupLabels":45,"otherNames":38},"Laboratory Biomarker Analysis","Correlative studies",[9,21],{"type":6,"name":47,"description":48,"armGroupLabels":49,"otherNames":50},"Medical Chart Review","Undergo medical record abstraction",[9,21],[51],"Chart Review",{"type":6,"name":53,"description":54,"armGroupLabels":55,"otherNames":56},"Quality-of-Life Assessment","Ancillary studies",[9,21],[57],"Quality of Life Assessment",{"type":6,"name":59,"description":54,"armGroupLabels":60,"otherNames":38},"Questionnaire Administration",[9,21],{"type":62,"name":63,"description":64,"armGroupLabels":65,"otherNames":66},"BEHAVIORAL","Smoking Cessation Intervention","Undergo usual care or NCCN-driven CTC\u002FDS",[9,21],[67],"Smoking and Tobacco Use Cessation Interventions",[69],{"name":70,"affiliation":5,"role":71},"Peter Shields, MD","PRINCIPAL_INVESTIGATOR",[73,78],{"name":74,"role":75,"phone":76,"phoneExt":38,"email":77},"The Ohio State University Comprehensive Cancer Center","CONTACT","800-293-5066","OSUCCCClinicaltrials@osumc.edu",{"name":79,"role":75,"phone":80,"phoneExt":38,"email":81},"Sarah Reisinger","614-366-4542","Sarah.Reisinger@osumc.edu",[83],{"facility":5,"status":84,"city":85,"state":86,"zip":87,"country":88,"countryCode":89,"cosmosGeoPoint":90,"geoPoint":95,"contacts":96},"RECRUITING","Columbus","Ohio","43210","United States","US",{"type":91,"coordinates":92},"Point",[93,94],-82.99879,39.96118,{"lat":94,"lon":93},[97,101],{"name":98,"role":75,"phone":99,"phoneExt":38,"email":100},"Peter G. Shields, MD","614-688-6563","peter.shields@osumc.edu",{"name":98,"role":71,"phone":38,"phoneExt":38,"email":38},{"type":71,"investigatorFullName":103,"investigatorTitle":104,"investigatorAffiliation":5,"oldNameTitle":38,"oldOrganization":38},"Peter Shields","Principal Investigator","100301098","beating-lung-cancer-in-ohio-protocol-in-improving-survival-in-patients-with-stage-iv-non-small-cell-lung-cancer-100301098",false,"NCT03199651","Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer","Beating Lung Cancer in Ohio (BLCIO) Protocol","BLCIO","Inclusion Criteria:\n\n* AIM 1-3\n* Pathologically confirmed stage IV NSCLC (with any Eastern Cooperative Oncology Group \\[ECOG\\] performance status, and any NSCLC - adenocarcinoma, squamous cell, etc.) with available imaging OR patients who do not yet have their staging completed, but in the judgment of the physician are likely to be stage IV;\n\n  * Patients may be enrolled if the recruiter cannot reach the patient by the first office visit, preferably prior to starting therapy and no later than one month after starting therapy; (NCCN guidelines allow for a switch to targeted therapy from chemotherapy if testing comes back positive after starting chemotherapy)\n* English speaking; and\n* Willing to provide access to medical records, insurance and billing data, biospecimens and respond to questionnaires, typically by phone, but possibly to include online or in-person surveys\n* AIM 3 ONLY\n* Patients must be current smokers who smoke at least one cigarette most days per week, or recent quitters who smoked at least one cigarette most days per week (\\\u003C 3 months); and\n* Household members must be current smokers, defined as smoking at least one cigarette most days per week\n* Hearing and vision impairments that would prevent ability to complete consent, interviews, or sample collection\n\nExclusion Criteria:\n\n* Being treated with definitive chemoradiotherapy or surgery\n* Receiving treatment for advanced lung cancer for over one month before enrollment; OR","ALL","18 Years",{"count":116,"type":117},3584,"ESTIMATED","INTERVENTIONAL",[120],"NA","This randomized clinical trial studies the Beating Lung Cancer in Ohio protocol in improving survival in patients with stage IV non-small cell lung cancer. The Beating Lung Cancer in Ohio protocol may help in evaluating immunotherapies and targeted therapies that prolong survival, have more favorable toxicity profiles than conventional chemotherapy and impact quality of life.",[123,124,125,126,127],"Cigarette Smoker","Current Smoker","Lung Adenocarcinoma","Squamous Cell Lung Carcinoma","Stage IV Non-Small Cell Lung Cancer","2026-06-15",{"date":130,"type":131},"2026-06-17","ACTUAL",{"date":133,"type":131},"2017-07-17",{"date":135,"type":117},"2028-12-31",{"name":5,"class":6},1]